Complete Genomics, a leading innovator in genomic sequencing, announced at the NextGen Omics & Spatial Biology Conference that it has partnered with BioTuring, developer of advanced bioinformatics ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

The use of biomarkers in medicine is transforming the way we detect diseases and develop treatments. Biomarkers are ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this ... The company's litigation against Parse's gene expression products remains ongoing, with additional asserted patents ...

Technology Networks speaks to the method’s pioneer, Paul Hebert. Read on to learn about how the technique went from ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

The substantial elimination of debt from the balance sheet, coupled with its transition towards profitability, positions the Company to leverage its strengthened financial position to accelerate ...

I was sorry to hear that 23andMe filed for Chapter 11 bankruptcy protection on Monday, but there would be a blizzard in Death ...

Advances in medicine mean more kids than ever beat cancer, but that’s just the beginning. Many childhood cancer survivors face long-term health challenges caused by the very treatments that saved them ...

March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq ... or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ...